CA2355820A1 - Formulations comprenant des liporegulateurs - Google Patents

Formulations comprenant des liporegulateurs Download PDF

Info

Publication number
CA2355820A1
CA2355820A1 CA002355820A CA2355820A CA2355820A1 CA 2355820 A1 CA2355820 A1 CA 2355820A1 CA 002355820 A CA002355820 A CA 002355820A CA 2355820 A CA2355820 A CA 2355820A CA 2355820 A1 CA2355820 A1 CA 2355820A1
Authority
CA
Canada
Prior art keywords
composition
lipid
propylene glycol
regulating agent
fenofibrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002355820A
Other languages
English (en)
Inventor
John M. Lipari
Dawn M. Raymond
Tom Reiland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2355820A1 publication Critical patent/CA2355820A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation comprenant un liporégulateur dissout dans au moins un ester d'acide gras du propylène-glycol servant de solvant primaire pour ce liporégulateur. Cette formulation peut également intégrer un ou plusieurs émulsifiants.
CA002355820A 1998-12-18 1999-12-15 Formulations comprenant des liporegulateurs Abandoned CA2355820A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21644898A 1998-12-18 1998-12-18
US09/216,448 1998-12-18
PCT/US1999/029696 WO2000037057A2 (fr) 1998-12-18 1999-12-15 Formulations comprenant des liporegulateurs

Publications (1)

Publication Number Publication Date
CA2355820A1 true CA2355820A1 (fr) 2000-06-29

Family

ID=22807109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002355820A Abandoned CA2355820A1 (fr) 1998-12-18 1999-12-15 Formulations comprenant des liporegulateurs

Country Status (4)

Country Link
EP (1) EP1140036A2 (fr)
JP (1) JP2002532539A (fr)
CA (1) CA2355820A1 (fr)
WO (1) WO2000037057A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2450238A1 (fr) * 2001-06-12 2002-12-19 Galephar M/F Composition pharmaceutique orale comprenant un derive de statine
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (fr) 2003-03-07 2011-12-13 Schering Corporation Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (fr) 2003-03-07 2008-08-27 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
JP2008522972A (ja) * 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド 脂肪酸エステルを有する安定性フェノフィブラート組成物
KR101390695B1 (ko) * 2006-08-01 2014-04-30 오츠카 세이야쿠 가부시키가이샤 약리 활성 물질의 흡수성이 개선된 의약 조성물
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
KR101702142B1 (ko) * 2008-10-22 2017-02-03 아유미 세이야쿠 가부시키가이샤 장관 흡수성을 개선하는 의약 조성물
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010098906A1 (fr) * 2009-02-24 2010-09-02 Madeira Therapeutics Formulations de statine liquide
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
TW201628625A (zh) 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU647563B2 (en) * 1990-12-18 1994-03-24 Aventisub Ii Inc. Enhanced bioavailability pharmaceutical composition containing probucol
WO1995014463A1 (fr) * 1993-11-25 1995-06-01 Taisho Pharmaceutical Co., Ltd. Composition de preparation pharmaceutique a absorption perorale amelioree
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
EP0998927A1 (fr) * 1998-10-30 2000-05-10 Fujirebio Inc. Composition pour augmenter l' absorption de derivés de l' acide pantothénique

Also Published As

Publication number Publication date
EP1140036A2 (fr) 2001-10-10
WO2000037057A3 (fr) 2000-11-16
JP2002532539A (ja) 2002-10-02
WO2000037057A2 (fr) 2000-06-29

Similar Documents

Publication Publication Date Title
CA2355820A1 (fr) Formulations comprenant des liporegulateurs
US6372251B2 (en) Formulations comprising lipid-regulating agents
MXPA01009840A (es) Nuevas formulaciones que comprenden agentes reguladores de lipido.
US6465011B2 (en) Formulations comprising lipid-regulating agents
CA2367995A1 (fr) Nouvelles formules comprenant des agents de regulation des lipides
US6326360B1 (en) Bubbling enteric coated preparations
US6838091B2 (en) Formulations comprising lipid-regulating agents
US20020102301A1 (en) Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6719999B2 (en) Formulations comprising lipid-regulating agents
US20040235935A1 (en) Oral pharmaceutical composition containing a statin derivative
US6814977B1 (en) Formulations comprising lipid-regulating agents
EP1183017A1 (fr) Formulations comprenant des agents regulateurs des lipides
MX2007012124A (es) Formulaciones mejoradas de fenofibrato.
US20020040046A1 (en) Novel formulations comprising lipid-regulating agents
US20050192340A1 (en) Simvastatin formulations and methods of making same
US7014864B1 (en) Formulations comprising lipid-regulating agents
JP2011526621A (ja) 経口バイオアベイラビリティが増大したフェノフィブラート製剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead